Stanford grad Jenny Duan rises $11M for Clair Health

Jenny Duan closed her seed round the same week she graduated from high school. Jenny graduated with a BS in symbolic systems at Stanford University. She also did an $11 million round of financing for Clair Health, which Fortune had learned, a company focused on chronic wound care.

Led by Khosla Ventures, a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC and Anne Wojcicki participated in the round. Co-founder Abhinav Agarwal is at the helm of developing what they are calling the first continuous and non-invasive hormone monitor for women.

Clair Health's wearable wristband takes the place of drawing blood or piercing skin to capture a woman's physiology, including skin temperature, heart rate variability, and electrodermal activity, which are analyzed by AI models to determine where she is at in her hormonal cycle. These 10 biosensors all of which Clair Health says are not found in any other consumer wearable capture physiological signals from the skin.

“Right now, to measure hormones, you either do a blood test in a lab or you pee on a stick at home,” Jenny told Fortune. “Any urine test is also not looking at hormones directly—they’re looking at how your body metabolizes them.”

Clair's AI also accurately predicted the phase of a woman's cycle 94% of the time, which is compared to a daily urine sample (not a clinical blood sample). There are independent third-party studies ongoing, including one at Stanford that will ultimately make harder numbers.

Key Highlights:

• Clair Health raised $11M seed funding led by Khosla Ventures for a hormone-tracking wearable
• The wrist device uses AI + skin sensors to non-invasively track women’s hormonal cycles
• The startup has a 25,000-user waitlist and aims to expand into fertility, PCOS, and menopause care

Other wearables firms have been prowling this area. Whoop began offering hormonal insights for women in 2025, and added a women-specific blood testing panel this spring. In February 2026, Smart ring maker Oura introduced its own AI model for Women's health. With Oura's temperature sensor, And Natural Cycles already provides FDA-cleared birth control. None of it was, however, developed specifically for hormones.

“Much of wearable technology being developed is bro-tech for tech-bros,” Dr. Alex Morgan, partner at Khosla Ventures, said in a statement to Fortune. “This team has identified the larger under addressed market of women interested in improving their health and wellness through getting insights specifically designed for women.”

The femtech industry will grow almost threefold from $39 Billion in 2024 to $97 Billion by 2030.

At the heart of Clair Health's case is the notion that the incumbents are taking a single hardware system and upgrading it. Everything in its sensor architecture came about because it sought to model the HPO axis—the hypothalamic-pituitary-ovarian system, the hormonal feedback loop that regulates almost every aspect of female physiology. It has provisional patents covering the sensor configuration.

“There’s only so much of a moat you can build with hardware,” Duan acknowledged. “What’s really special is the machine learning approach and the biophysical modeling.”

Clair's first step is to launch as a wellness product in November, and then apply for FDA clearance in the coming weeks—the quicker road to market. The company already has a waitlist of 25,000 users, and has presold its users. Has gotten over 100 letters of intent from fertility clinics. A longer-term plan should involve tracking for perimenopause, tailoring hormone replacement therapy and diagnostic testing for possible issues such as PCOS and endometriosis.

The company is working towards HIPAA compliance by implementing zero-knowledge encryption and on-device computing for women who do not want to leave their health data in the cloud.